300+ investors in your industry, stage, and region Get
Any industry
EdTech
Venture Capital
Video Games
Hospitality
Restaurants
Crowdfunding
Financial Services
Construction
Photography
Cryptocurrency
Digital Media
Big Data
Email
Artificial Intelligence
Clean Energy
Non Profit
Social Impact
Energy
SaaS
Google
CleanTech
Consumer
Health Care
Enterprise Software
Local
Travel
Platforms
InsurTech
Mobile
Oil and Gas
Payments
Retail
Film
Marketplace
Fitness
Organic Food
Machine Learning
Agriculture (AgTech)
Gaming
B2B
Social Network
Medical Device
Wellness
Education
Sports
Legal
Automotive
eSports
Biotechnology
Renewable Energy
Facebook
Blockchain
Software
Theatre
Medical
Web3
Recruiting
Beauty
Fashion
Infrastructure
Social
Celebrity
Cannabis
LGBT
Climate
Food and Beverage
Life Science
Publishing
Wine and Spirits
Mobile Apps
Real Estate
Sporting Goods
Music
Art
Finance
Manufacturing
FinTech
Social Media
Franchise
Internet
Mobile Advertising
Android
Impact
Proptech
Hardware
Transportation
Biotech
Sustainability
Enterprise
Community
Media (Entertainment)
Any country
Afghanistan
Greece
Thailand
United Arab Emirates
Andorra
Dominica
Japan
Brazil
Singapore
Burkina Faso
Africa
LATAM
Egypt
Faroe Islands
South Korea
United Kingdom
Oceania
Argentina
Tunisia
Taiwan
Zimbabwe
Hong Kong
Benin
Nigeria
Togo
Croatia
Gibraltar
Guinea
Kyrgyzstan
Norway
Haiti
Sudan
Malawi
Isle of Man
Iran
Madagascar
Lesotho
Russian Federation
Turkey
Liberia
Nepal
Pakistan
Mexico
Tajikistan
Sweden
Zambia
Romania
Puerto Rico
Oman
Poland
Guernsey
Cameroon
Colombia
China
Armenia
Costa Rica
Côte d'Ivoire
Czech Republic
Marshall Islands
Kuwait
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
Australia
Morocco
New Zealand
Jamaica
Sri Lanka
Guatemala
Switzerland
Kazakhstan
Cayman Islands
Venezuela
Myanmar
Uganda
Uruguay
Moldova
Seychelles
Paraguay
Botswana
South Africa
France
Denmark
Georgia
Ghana
Iraq
Philippines
Portugal
Sierra Leone
El Salvador
Senegal
India
Germany
Canada
Ireland
Saudi Arabia
Latvia
Kenya
Mali
Malaysia
Rwanda
Tanzania
United States
Indonesia
Middle East
Dominican Republic
Bermuda
Asia
Albania
Spain
Angola
Europe
Cyprus
Qatar
Bangladesh
Barbados
Belgium
Austria
Ethiopia
Jordan
Azerbaijan
Ecuador
Bulgaria
Bahamas
Bahrain
Jersey
Estonia
Bolivia
Belize
Algeria
Belarus
Finland
Italy
Hungary
Grenada
Israel
Honduras
Lithuania
Cambodia
Iceland
Liechtenstein
Lebanon
Mongolia
Peru
Slovenia
San Marino
Ukraine
Vietnam
Chile
Angel Investors
VC Funds
All Investors
Access Full Database - Free Forever
Open database
Robert Nelsen, Co-Founder & Managing Director at ARCH Venture Partners

Robert Nelsen

Co-Founder & Managing Director @ ARCH Venture Partners

New York, United States

Robert Nelsen is a Series B investor at ARCH Venture Partners in New York focused on Biotechnology and Health Care. Robert Nelsen is based out of Boston, Massachusetts, and is the Co-founder and Managing Director of ARCH Venture Partners. Robert previously worked at Seaport Therapeutics as a Board of Directors. Robert Nelsen attended the University of Puget Sound.

Total investments:
98
Last investment:
Lead investor:
37%

Last updated:

Industries Robert Nelsen invests in

BiotechnologyHealth CareTherapeuticsMedicalLife Science

Stages Robert Nelsen invests in

Series BSeries ASeries CSeedVenture - Series Unknown

Countries Robert Nelsen invests in

United StatesChinaUnited KingdomIsrael

Round sizes

Series A $15M–$216MSeries B $25M–$200MSeries C $31M–$205M

Contacts

TypeContactValidation
Work email
Personal email
Work phone
Personal phone
Socials

Sign up to unlock verified contacts

Unlock Contacts

Round size

Series A
$15M–$216M
Series B
$25M–$200M
Series C
$31M–$205M

Investment Focus

Industry

  • Biotechnology 37 (38%)
  • Health Care 30 (31%)
  • Therapeutics 14 (14%)
  • Medical 11 (11%)
  • Life Science 11 (11%)
See all 51 industries →

Stage

  • Series B 31 (32%)
  • Series A 30 (31%)
  • Series C 12 (12%)
  • Seed 7 (7%)
  • Venture - Series Unknown 5 (5%)
See all 10 stages →

Country

  • United States 49 (50%)
  • China 2 (2%)
  • United Kingdom 2 (2%)
  • Israel 1 (1%)

Investments

CompanyDescriptionRoundLinks
Moonwalk Biosciences is a genomic medicine startup that aims to provide a new class of precision epigenetic therapeutics. The company is working on the development of a profiling and engineering technology platform that, with the help of advanced artificial intelligence prediction, provides a comprehensive view of the epigenome in health anddisease, allowing healthcare providers to take a fresh look at how therapies are discovered and developed. $70M / Series B / Sep 08, 2026
Astromech develops artificial intelligence applications for biotechnology research and development. The company focuses on creating AI platforms that support genetic engineering and synthetic biology initiatives. Its work combines operational expertise in biotechnology ventures with scientific knowledge in genetics, enabling the development ofAI-driven tools for research environments. It operates in a confidential manner, concentrating on technology development without publicly disclosing specific products or applications. Leadership integrates experience in managing complex research projects with advanced scientific insight to guide the company's growth and AI platform development. The company maintains a corporate structure that supports institutional investment while continuing its focus on AI and biotechnology innovation. $20M / Seed / Aug 20, 2026
Discovering powerful new drugs from eukaryotic microbes by combining Genomics with AI and Synthetic Biology. Founded by Gregory Verdine, PhD, Rick Klausner, MD and WeiQing Zhou, MBA, LifeMine Therapeutics is headquartered in Cambridge, Massachusetts. $188M / Series E / Aug 06, 2026
Trase provides and implements complete AI agent solutions, allowing businesses to automate complicated administrative procedures and operations in a safe and secure manner. $107M / Seed / Jun 24, 2026
City Therapeutics is a biopharmaceutical company focusing on engineering next-generation small-interfering RNAs (siRNAs) to enhance RNAi-based therapies. The company develops a pipeline of innovative RNAi therapeutics aimed at addressing various disease indications. City Therapeutics prioritizes improving and expanding RNAi technology to achievebetter patient outcomes. The leadership team includes experienced scientists and industry professionals dedicated to advancing the field of RNA interference. $99.5M / Series B / Jun 08, 2026
Paradigm is rebuilding the clinical research ecosystem by developing a platform that allows all patients equitable access to trials while improving trial efficiency and lowering barriers to participation for healthcare providers. $78M / Series B / Dec 04, 2025
SciNeuro Pharmaceuticals is a clinical-stage biotechnology company focused on developing groundbreaking therapies for neurodegenerative diseases. Since its founding in 2020, SciNeuro has built a portfolio of pipeline programs staged from discovery to clinical development by addressing three key disease-driving mechanisms of neurodegeneration –neurovascular inflammation, proteinopathy, and immune response. The company aims to develop disease-modifying treatment options for Alzheimer’s disease, Parkinson’s disease, and other devastating CNS diseases. $53M / Venture - Series Unknown / Dec 04, 2025
Dispatch Bio helps create a world where all cancer patients can be cured. $216M / Series A / Jul 23, 2025
Be Biopharma is developing B cells as medicines. $92M / Series C / Jan 15, 2025
Be Biopharma is developing B cells as medicines. $82M / Venture - Series Unknown / Oct 22, 2024
See all 98 investments →

Co-Investors

ARCH Venture Partners

About ARCH Venture Partners

VC Fund · Chicago, United States

ARCH invests primarily in companies co-founded by scientists and entrepreneurs, concentrating on bringing to market innovations in life sciences. They enjoy special recognition as a leader in the successful commercialization of technologies developed at academic research institutions and national laboratories. ARCH has raised ten venture funds totaling over $3 billion and has invested in the venture capital rounds for more than 150 companies. ARCH investors include corporations, pension funds, endowment funds, financial institutions, and private investors.

ARCH Venture Partners Contacts

NameEmailPhoneSocials
Cindy Bayley
Cindy Bayley Affiliate
Clinton Bybee
Clinton Bybee Co-Founder and Managing Director
Hong Hou
Hong Hou Venture Partner
Keith Crandell
Keith Crandell Co-founder & Managing Director
Kristina Burow
Kristina Burow Managing Director

Sign up to unlock verified contacts

Unlock Contacts

See all 17 contacts →

Access 48,091 investors

822 industries, 177 countries. Updated daily. Emails and phones included.

Browse database — It's Free!

Find investors for your startup

Search 48,091 investors by industry and country. Emails and phones included.

Any industry
EdTech
Venture Capital
Video Games
Hospitality
Restaurants
Crowdfunding
Financial Services
Construction
Photography
Cryptocurrency
Digital Media
Big Data
Email
Artificial Intelligence
Clean Energy
Non Profit
Social Impact
Energy
SaaS
Google
CleanTech
Consumer
Health Care
Enterprise Software
Local
Travel
Platforms
InsurTech
Mobile
Oil and Gas
Payments
Retail
Film
Marketplace
Fitness
Organic Food
Machine Learning
Agriculture (AgTech)
Gaming
B2B
Social Network
Medical Device
Wellness
Education
Sports
Legal
Automotive
eSports
Biotechnology
Renewable Energy
Facebook
Blockchain
Software
Theatre
Medical
Web3
Recruiting
Beauty
Fashion
Infrastructure
Social
Celebrity
Cannabis
LGBT
Climate
Food and Beverage
Life Science
Publishing
Wine and Spirits
Mobile Apps
Real Estate
Sporting Goods
Music
Art
Finance
Manufacturing
FinTech
Social Media
Franchise
Internet
Mobile Advertising
Android
Impact
Proptech
Hardware
Transportation
Biotech
Sustainability
Enterprise
Community
Media (Entertainment)
Any country
Afghanistan
Greece
Thailand
United Arab Emirates
Andorra
Dominica
Japan
Brazil
Singapore
Burkina Faso
Africa
LATAM
Egypt
Faroe Islands
South Korea
United Kingdom
Oceania
Argentina
Tunisia
Taiwan
Zimbabwe
Hong Kong
Benin
Nigeria
Togo
Croatia
Gibraltar
Guinea
Kyrgyzstan
Norway
Haiti
Sudan
Malawi
Isle of Man
Iran
Madagascar
Lesotho
Russian Federation
Turkey
Liberia
Nepal
Pakistan
Mexico
Tajikistan
Sweden
Zambia
Romania
Puerto Rico
Oman
Poland
Guernsey
Cameroon
Colombia
China
Armenia
Costa Rica
Côte d'Ivoire
Czech Republic
Marshall Islands
Kuwait
Luxembourg
Malta
Mozambique
Namibia
Mauritius
Nicaragua
Panama
Serbia
Uzbekistan
Australia
Morocco
New Zealand
Jamaica
Sri Lanka
Guatemala
Switzerland
Kazakhstan
Cayman Islands
Venezuela
Myanmar
Uganda
Uruguay
Moldova
Seychelles
Paraguay
Botswana
South Africa
France
Denmark
Georgia
Ghana
Iraq
Philippines
Portugal
Sierra Leone
El Salvador
Senegal
India
Germany
Canada
Ireland
Saudi Arabia
Latvia
Kenya
Mali
Malaysia
Rwanda
Tanzania
United States
Indonesia
Middle East
Dominican Republic
Bermuda
Asia
Albania
Spain
Angola
Europe
Cyprus
Qatar
Bangladesh
Barbados
Belgium
Austria
Ethiopia
Jordan
Azerbaijan
Ecuador
Bulgaria
Bahamas
Bahrain
Jersey
Estonia
Bolivia
Belize
Algeria
Belarus
Finland
Italy
Hungary
Grenada
Israel
Honduras
Lithuania
Cambodia
Iceland
Liechtenstein
Lebanon
Mongolia
Peru
Slovenia
San Marino
Ukraine
Vietnam
Chile
Angel Investors
VC Funds
All Investors

Similar Investors

Recommended lists

FAQ

What does Robert Nelsen invest in?

Robert Nelsen invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series B and Series A stage. Most of the 98 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

What round sizes does Robert Nelsen invest in?

Robert Nelsen typically joins rounds of $15M–$216M at Series A, $25M–$200M at Series B and $31M–$205M at Series C. These are whole funding-round sizes, not Robert Nelsen's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Robert Nelsen took part in.

How do I contact Robert Nelsen?

Public channels for Robert Nelsen include X (Twitter). For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

When did Robert Nelsen last invest?

The most recent investment recorded for Robert Nelsen closed in Sep 2026. Shizune tracks 98 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Nov 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

Contact your first 100 investors today

Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.

Find investors — It's Free!
Robert Nelsen Robert Nelsen Find email